Obesity News

Adults with type 1 diabetes using either semaglutide or tirzepatide off-label had greater decreases in body weight and HbA1c than those not treated with either medication, according to a speaker.

Among patients with Barrett’s esophagus, every 5 kg/m2 increase in BMI was associated with up to a 6% relative increase in the risk for malignant progression, according to a systematic review and meta-analysis.

Excessive abdominal fat was tied to chronic pain across multiple sites, particularly in women, an analysis published in Regional Anesthesia & Pain Medicine showed.

Use of glucagon-like peptide-1 receptor agonists was associated with a reduced risk for progression to cirrhosis and other complications in patients with metabolic dysfunction-associated steatotic liver disease and diabetes, data showed.

In a first-in-human study, a novel oral amylin and GLP-1 receptor coagonist was safe and tolerable and lowered weight compared with placebo at 12 weeks in patients with obesity, researchers reported.

In patients with obesity and heart disease, semaglutide 2.4 mg reduced risk for major adverse cardiovascular events regardless of baseline kidney function, according to new data from the SELECT trial.

A once-weekly GLP-1/glucagon dual agonist conferred greater decreases in HbA1c and body weight than the GLP-1 receptor agonist dulaglutide for adults with type 2 diabetes, according to a presenter.

Intermittent and continuous energy restriction diets both improved cardiometabolic measures and reduced symptoms of depression and disordered eating among adolescents with obesity, according to findings published in JAMA Pediatrics.

A dual GLP-1/GLP-2 receptor agonist did not confer greater body weight reductions for adults with obesity and without diabetes at 12 weeks compared with placebo, according to data from a phase 2a proof-of-concept study.